Clinical trials: Low or Intermediate Risk Prostate Cancer
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
High-Dose Stereotactic Radiation for Prostate Cancer
This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01664130
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
We are studying whether men being treated for prostate cancer have the same amount of side effects from either one of two different external radiation treatments: IMRT or PBT.
- Trial name
- PARTIQoL (NCT01617161)
- Testing
- Proton Beam Therapy, Intensity Modulated Radiation Therapy
- Where
- 13 sites in United States
- Volunteers
- 454 people
- Sponsor
- Massachusetts General Hospital
Low or Intermediate Risk Prostate Cancer
Advanced Imaging for Radiotherapy Treatment Planning and Guidance for Low-Intermediate Risk Prostate Cancer (Margin)
The integration of magnetic resonance imaging (MRI) in the treatment planning process for prostate cancer will reduce uncertainties in delineation of the prostate gland, and will enable delineation of the urethra, penile bulb…
- Trial name
- NCT00890006
- Testing
- Advanced imaging for radiotherapy planning and guidance
- Where
- Canada
- Volunteers
- 99 people
- Sponsor
- University Health Network, Toronto
Intermediate Risk Prostate Cancer, Castration-resistant Prostate Cancer
VAccination in Early and ADvanced Prostate caNCEr
This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer.
- Trial name
- ADVANCE (NCT03815942)
- Testing
- ChAdOx1-MVA 5T4 vaccine, Nivolumab Infusion [Opdivo]
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Oxford
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer
This phase II trial studies how well focal radiation therapy with stereotactic body radiation therapy (SBRT) or high-dose rate (HDR) brachytherapy works in treating patients with low or intermediate-risk prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- NCT04399824
- Testing
- High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer Patients Treated by Radiotherapy
Two-fraction Proton Therapy With MRI Guidance for Prostate Cancer: A Phase II Trial
This study is testing a shorter treatment method for prostate cancer using proton therapy (PT), which is very precise and may cause fewer side effects compared to traditional radiation.
- Trial name
- PT2 (NCT07130682)
- Testing
- Pencil Beam Proton Therapy Treatment Machine
- Where
- Hong Kong
- Volunteers
- 35 people
- Sponsor
- Hong Kong Sanatorium & Hospital
Prostate Cancer
Stereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate Cancer
The primary goal of this phase II study is to compare the change of EPIC HRQOL scores (1-year minus baseline) between SBRT and IMRT.
- Trial name
- NCT02339701
- Testing
- IMRT, SBRT
- Where
- Hong Kong
- Volunteers
- 68 people
- Sponsor
- Chinese University of Hong Kong
Localized Prostate Cancer, Low Risk Prostate Cancer
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
The investigators want to investigate whether it is possible to reduce the number of curative radiotherapy doses from 5 to only 3 for men with localized early prostate cancer.
- Conditions
- Localized Prostate Cancer, Low Risk Prostate Cancer, Intermediate Risk Prostate Cancer
- Trial name
- PRECISION (NCT06117059)
- Testing
- 3 fractions of prostate SBRT
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- NHS Lothian
Prostate Cancer
Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform
In this non-interventional study, men being seen by urologists in the course of their normal practice that present with clinical suspicion of prostate cancer (based on DRE, elevated Prostate Specific Antigen (PSA), and/or family…
- Trial name
- NCT04100811
- Where
- 3 sites in United States
- Volunteers
- 2,019 people
- Sponsor
- miR Scientific LLC
Prostate Cancer
Evaluation of Four Treatment Modalities in Prostate Cancer With Low or "Early Intermediate" Risk
4arms preference based Study to compare four therapy options in prostate cancer with low or early intermediate risk
- Trial name
- PREFERE (NCT01717677)
- Testing
- radical prostatectomy, percutaneous radiation therapy, permanent seed implantation
- Where
- 2 sites in Germany
- Volunteers
- 457 people
- Sponsor
- Association of Urologic Oncology (AUO)
Prostate Cancer
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
The aim of this prospective, single-arm phase II study is the individualization of both radiotherapy (RT) and androgen deprivation therapy (ADT) duration for patients with high-risk localized prostate cancer (PCa) according to…
- Trial name
- HypoPro (NCT06772441)
- Testing
- Androgen deprivation therapy (ADT)
- Where
- Cyprus
- Volunteers
- 30 people
- Sponsor
- German Oncology Center, Cyprus
Prostate Cancer
Single Fraction Early Prostate Irradiation (SiFEPI)
Recently, HDR brachytherapy delivering only a 19 Gy fraction was proposed as exclusive treatment for low and intermediate risk prostate cancers.
- Trial name
- SiFEPI (NCT02104362)
- Testing
- exclusive single-fraction irradiation
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Centre Antoine Lacassagne
Prostate Cancer
Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy.
- Trial name
- NCT00002723
- Testing
- suramin
- Where
- 27 sites in United States, South Africa
- Volunteers
- 390 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance Regimen
Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging
Trans-perineal focal laser ablation represents a promising alternative focal therapy option for patients with low-risk or favorable intermediate risk prostate cancer.
- Trial name
- NCT05826470
- Testing
- TRANBERG®|Thermal Therapy System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Genesis Research LLC
Prostate Cancer
Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)
This study will enroll prostate cancer patients with an unfavorable intermediate- or high-risk diagnosis. The purpose of this study is to determine whether a regimen of pembrolizumab and low dose prostate radiation or low dose…
- Trial name
- TALON (NCT04569461)
- Testing
- pembrolizumab, Low dose prostate radiation, Radical Prostatectomy
- Where
- United States
- Sponsor
- Duke University
Adenocarcinoma of Prostate
Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer
The overall goal of this project is to test an interactive, multi-media decision aid in the form of an electronic clinical decision dashboard designed to improve the quality of clinical decision making for initial treatment of…
- Trial name
- NCT02342626
- Testing
- Dashboard
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- University of Rochester
Prostate Adenocarcinoma
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of intermediate risk of prostate cancer presenting for definitive radiation treatment with…
- Trial name
- NCT01352429
- Testing
- Proton Therapy, IMRT
- Where
- 2 sites in United States
- Volunteers
- 303 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC V7
Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer
This randomized phase III trial studies a diet and exercise program based on the Diabetes Prevention Program to promote weight loss and improve health in men with low-risk or low-intermediate-risk prostate cancer on active…
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC V7, Stage IIA Prostate Cancer AJCC v7
- Trial name
- PALS (NCT02454517)
- Testing
- Behavioral Dietary Intervention, Exercise Intervention, Informational Intervention
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer, Ultrasound Therapy
Evaluation of HIFU in TREATMENT OF LOCALIZED PROSTATE CANCER and OF RECURRENCE AFTER RADIOTHERAPY
to compare the efficacy of HIFU treatment with standard treatment in two situations: 1. as first-line cancer treatment, HIFU is compared to radical prostatectomy. 2.
- Trial name
- HIFI (NCT04307056)
- Testing
- Radical Prostatectomy, High Intensity Focused Ultrasound (HIFU) Treatment
- Where
- 49 sites in France, Guadeloupe
- Volunteers
- 3,862 people
- Sponsor
- Association Francaise d'Urologie
Low or Intermediate Risk Prostate Cancer
Phase I Study MR-guided SBRT to PCa
1) investigate the feasibility, tolerance, and safety of dose escalation via MR-guided stereotactic body radiation therapy and simultaneous integrated boost to the dominant intraprostatic lesions (DILs), 2) to assess the…
- Trial name
- MRgRTPCa (NCT03935308)
- Testing
- MR guided Linear Accelerator
- Where
- United States
- Sponsor
- Henry Ford Health System